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3D Molecular modelingAbstract The present paper reports the synthesis and characterization of some new oxovanadium(IV)
complexes of composition [VO(L)2(H2O)]ÆH2O, where LH= N-(40-butyrylidene-30-methyl-10-phe-
nyl-20-pyrazolin-50-one)sulfadiazine (bumphp-sdzH), N-(40-butyrylidene-30-methyl-10-phenyl-20-pyr-
azolin-50-one)sulfaguanidine (bumphp-sgnH), N-(40-butyrylidene-30-methyl-10-phenyl-20-pyrazolin-
50-one)sulfani-lamide (bumphp-snmH), and N-(40-butyrylidene-30-methyl-10-phenyl-20-pyrazolin-
50-one)sulfamerazine (bumphp-smrH). These complexes were prepared by the reaction of vanadyl
sulfate pentahydrate with the ligands in 1:2 metal–ligand ratios, in ethanol. The compounds so
obtained were characterized by different physicochemical studies, such as, elemental analyses,
molar conductance, and magnetic measurements, thermogravimetry, cyclic voltammetry, infrared,
electron spin resonance, and electronic spectral studies. The overall IR studies conclude that the
ligands in the present investigation behave as monobasic bidentate O,N-donors. The 3D molecular
Oxovanadium(IV) complexes of medicinal relevance: Synthesis, characterization, and 3D-molecular modeling 79modeling and analysis for bond lengths and bond angles have also been carried out for one of the
representative compounds, [VO(bumphp-sdz)2(H2O)]ÆH2O (1) to substantiate the proposed
structure. Based on these studies suitable octahedral structures have been proposed for these
complexes.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Acylpyrazolones, originally investigated by Jensen (1959a,b),
have been employed for several applications (Marchetti et al.,
2000a,b), viz., as pigments for dyes, as metal extractants from
acidic solutions and also as sequestering agents toward pollut-
ing metal ions, such as cadmium and lead. These ligands have
played and continue to play an important role in the develop-
ment of coordination compounds that have found wide appli-
cation in several ﬁelds, from new materials to catalysts, as
precursors for CVD in the microelectronic industry and as
potential antitumourals (Marchetti et al., 2005).
The pyrazolone derivatives have been reported to possess
strong antibacterial, antihistaminic and antifungal, analgesic,
antipyretic, anti-inﬂammatory, and anti-rheumatic activities
(Merck Index, 1983). They also show antidiabetic (Goodman
and Gilman, 1970), anticancer (Garg and Singh, 1970), and
antineoplastic (Wilson and Bottigleri, 1962) properties.
The derivatives of Sulfonamide exhibit a range of bioactivi-
ties, including anti-angiogenic (Funahashi et al., 2002; Semba
et al., 2004), anti-tumor (Semba et al., 2004; Sawi´nski et al.,
2005), anti-inﬂammatory and anti-analgesic (Chen et al.,2005),
anti-tubercular (Gadad et al., 2004), anti-glaucoma (Agrawal
et al., 2004), anti-HIV (Yeung et al., 2005), cytotoxic (Encı´o
et al., 2005), anti-microbial (Nieta et al., 2005), and anti-malarial
(Domı´nguez, et al., 2005) agents. The sulfonamide derivatives
are also known to exhibit a wide variety of pharmacological
activities (Yoshino et al., 1992; Toth et al., 1997; Medina et al.,
1999) through exchanges of different functional groups without
themodiﬁcation of the structural –S(O)2N(H)– feature. The syn-
thesis of metal sulfonamide compounds had received much
attention due to the fact that sulfanilamides were the ﬁrst effec-
tive chemotherapeutic agents to be employed for the prevention
and cure of bacterial infections in humans (Mohamed and
Gad-Elkareem, 2007). The pharmacological activity of these
types ofmolecules is often enhanced by complexationwithmetal
ions (Bult and Sigel, 1983; Casanova et al., 1983). Moreover,
some metal complexes of these ligands have been found to pro-
mote rapid healing of burns in human and animals (De Oliveira
et al., 2008; Baenziger et al., 1983).
Vanadium plays an important role in life and one of its
most relevant properties identiﬁed thus for is its capacity to
act as an insulin-enhancing agent, either in the form of its inor-
ganic salts or complexes with organic ligands (Rangel et al.,
2006). It has been observed that simple inorganic vanadium
compounds are more toxic than vanadium compounds with
organic ligands and the efﬁcacy of metal based therapeutic
agents’ changes drastically by making changes in the organic
ligands that are attached to the metal center (Mahroof-Tahir
et al., 2005). For any complex considered for therapeutic
use, it is important to consider the intrinsic toxicity of the
ligand, especially if the treatment is predicted for long periods
(Pressoa et al., 2003). Great efforts have, therefore, been madeto synthesize oxovanadium(IV) complexes of high biological
activity and low toxicity which are readily absorbed. Many
oxovanadium(IV) complexes with various coordination modes
(Thompson and Orvig, 2001; Sakurai et al., 2002; Thompson
et al., 1999; Maurya and Rajput, 2006; Ghosh et al., 2005)
have been prepared, viz., VO(O4), VO(S2N2), VO(S4),
VO(N3O), and VO(N2O2), and the relationship between their
structures and insulin-mimetic activities has been examined
by evaluating both in vivo and in vitro results. The bis(ethylm-
altolato)oxovanadium(IV) (BEOV) has completed phase I clin-
ical trial in humans in the treatment of type-1 and type-2
diabetes mellitus (Thompson and Orvig, 2006).
Besides the antidiabetic action, vanadium complexes are
known to possess potent anticancer activity (Kieler et al.,
1965; Dessoize, 2004), which deserves increasing attention
for the application to biomedical sciences (Etcheverry et al.,
2008). Recent studies indicate the chemopreventive efﬁcacy
of vanadium in the inhibition of chemically induced carcino-
mas of the liver, colon, and mammary gland and has substan-
tially documented the role of vanadium in the prevention of
DNA–protein crosslinks, DNA chain break, chromosomal
aberrations (Molinuevo et al., 2008; Chakraborty et al.,
2006; Chattopadhyay et al., 2005; Kanna et al., 2004, 2005;
Ray et al.,2004, 2005), reduction of tumor incidence and aver-
age number of tumors (33, Bishayee et al., 2000; Kanna et al.,
2003), suppression of tumor marker genes like GST, GST-P,
GGT, and MT (Ray et al., 2004). On the other hand, when
using in vitro models it has been shown that some vanadium
complexes displayed antitumoural actions (Barrio et al.,
2003; D’Cruz and Uckun, 2002; Ding et al., 1999; Etcheverry
et al., 2002; Evangelou et al., 2002; Molinuevo et al., 2004).
Knowledge gained from in vitro studies has advanced vana-
dium research into the preclinical in vivo phase (Bishayee
et al., 2010).
It has also been recognized that vanadium as a micronutri-
ent prevents the minor wear and tear of the essential critical
molecules of the cell like DNA, proteins, etc. in humans
(Fenech and Ferguson, 2001) Thus, it has a role in DNA main-
tenance reactions and may protect the genomic instability that
may be leading to cancer (Ray et al., 2006).
Recent studies (D’Cruz et al., 2003; Shigeta et al., 2003)
showed that oxovanadium complexes of thiourea and vana-
dium substituted polyoxotungstates exhibit potent anti-HIV
properties toward infected immortalized T-cells. However,
the instability of vanadium(IV) complexes under physiological
conditions has been frequently encountered (Raymond et al.,
2007). Some oxovanadium(IV) complexes of porphyrin deriv-
atives {[VO(N4)] type} were evaluated for their inhibitory
effects on HIV-1(BaL) (Human Immunodeﬁciency Virus) rep-
lication in Hut/CCR5 cells (Raymond et al., 2007).
Earlier reports from our laboratory described the synthesis
and characterization of metal chelates of ruthenium(II)
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Figure 1 Keto-enol tautomerism and intramolecular hydrogen bonding in Schiff bases.
Figure 2 IR spectrum of bumphp-snmH (III).
80 R.C. Maurya et al.2004, in press), oxovanadium(IV) (Maurya and Rajput, 2006),
Cu(II), Ni(II), Co(II), Zn(II), Sm(III), Th(IV), and U(VI)O2
(Maurya et al., 2007) chelates with some Schiff base ligands
derived from sulfa drugs.Considering the pronounced biological activity of acy-
lpyrazolones, and of sulfa drug derivatives, in view of the impor-
tance of vanadium compounds mentioned above, and also
extending our search formore efﬁcacious vanadium compounds,
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nadium(IV) complexes {[VO(N2O2)] type} involving pyrazolone
based sulfa drug Schiff bases, viz., N-(40-butyrylidene-30-methyl-
10-phenyl-20-pyrazolin-50-one)sulfadiazine (bumphp-sdzH, I),
N-(40-butyrylidene-30-methyl-10-phenyl-20-pyrazolin-50-one)sul-
faguanidine (bumphp-sgnH, II), N-(40-butyrylidene-30-methyl-
10-phenyl-20-pyrazolin-50-one)sulfanilamide (bumphp-snmH,
III), and N-(40-butyrylidene-30-methyl-10-phenyl-20-pyrazolin-
50-one)sulfamerazine (bumphp-smrH, IV) (Fig. 1). The present
communication describes the results of such a study.
2. Experimental
2.1. Materials
Vanadyl sulfate pentahydrate, calcium hydroxide, butyryl
chloride, dimethyl formamide, sulfa drugs, viz., sulfamerazine
(Thomas Baker Co. Ltd., Mumbai, India), sulfadiazine, sul-
phaguanidine and sulfanilamide (Sigma Chemicals Co.,
USA), and 3-methyl-1-phenyl-2-pyrazolin-5-one (Lancaster
Research Chemicals, England) were used as supplied. All other
chemicals used were of analytical grade.
2.2. Preparation of 3-methyl-1-phenyl-4-butyryl-2-pyrazolin-5-
one (bumphpH)
It was prepared by the method reported elsewhere (Jensen,
1959a,b) with modiﬁcation. Into a 1-L 3-necked quick ﬁt ﬂask
containing DMF (100 mL) and carrying a dropping funnel, a
mechanical stirrer, and a reﬂux condenser was placed 3-
methyl-1-phenyl-2-pyrazolin-5-one (17 g, 0.098 mol). A solu-
tion was obtained by gentle heating and stirring. Calcium
hydroxide (10 g, 0.14 mol) was added and butyryl chloride
(10.33 mL) was added drop wise within 2–3 min. The reaction
was exothermic and the reaction mixture became a paste. The
mixture was allowed to cool and then reﬂuxed with stirring for
1 h on a sand bath, during which period, the bright yellow
complex, formed initially, turned yellowish brown. The com-
plex was decomposed by pouring the reaction mixture into
chilled dilute hydrochloric acid solution (500 mL, 2 N). A yel-Table 1 Characterization data of the synthesized sulfa drug Schiff
S. No. Schiﬀ bases (empirical formula) (F.W.) Found/(calcd.)%
C H
I bumphp-sdzH (C24H24N6SO3) (476) 60.12 (60.50) 5.38
II bumphp-sgnH (C21H24N6SO3) (440) 57.59 (57.27) 5.78
III bumphp-snmH (C20H22N4SO3) (398) 60.13 (60.30) 5.38
IV bumphp-smrH (C25H26N6SO3) (490) 61.56 (61.22) 5.16
Table 2 IR spectral data of the synthesized ligands.
S. No. Ligands m(C‚N) (azomethine) m(C–O) (enolic)
I bumphp-sdzH 1630 1159
II bumphp-sgnH 1627 1138
III bumphp-snmH 1627 1179
IV bumphp-smrH 1628 1153lowish brown solid settled, which was ﬁltered on a sintered
glass crucible, washed with distilled water until the washings
were colorless and dried in air and recrystallized from n-hep-
tane. Melting point, 65 C, yield, 70%.
2.3. Synthesis of Schiff bases
The Schiff bases with sulfa drugs were prepared as follows: An
ethanolic solution (15 mL) of bumphpH (0.488 g, 2 mmol) was
added to the solution of sulfadiazine (0.500 g, 2 mmol), sulfa-
nilamide (0.344 g, 2 mmol), sulfaguanidine (0.428 g, 2 mmol),
or sulfamerazine (0.528 g, 2 mmol) in ethanol. The resulting
solution was reﬂuxed with stirring for 4–5 h and then ﬁltered
to remove the insoluble sulfa drug, if any. The ﬁltrate so
obtained was concentrated on a water bath and left overnight
at room temperature when colored crystals of Schiff bases sep-
arated out from their respective solutions. The crystals thus
obtained were washed with ethanol and dried in vacuo. The
characterization data of Schiff bases are given in Tables 1
and 2.
2.4. Synthesis of complexes
The following general procedure was used in the synthesis of
all the complexes. The salt VOSO4Æ5H2O (0.253 g, 1 mmol)
was dissolved in 5 mL of water and this solution was added
to a warmed, stirred ethanolic solution (15 mL) of the corre-
sponding Schiff bases, bumphp-sdzH (0.952 g, 2 mmol),
bumphp-sgnH (0.880 g, 2 mmol), bumphp-snmH (0.796 g,
2 mmol) or bumphp-smrH (0.980 g, 2 mmol). The resulting
solution was reﬂuxed for 10–12 h and then concentrated to
half of its volume. The resulting colored precipitate was ﬁltered
and washed several times with ethanol to remove the unreacted
ligand and the metal salt. The product was dried in vacuo. The
analytical data are given in Table 3.
2.5. Analyses
Carbon, hydrogen, and nitrogen were determined micro-ana-
lytically at SAIF, Indian Institute of Technology, Mumbai.base ligands.
Color Decomp. temp. (C)
N
(5.04) 17.30 (17.65) Light golden yellow 200
(5.45) 19.41 (19.09) Yellow 150
(5.53) 14.39 (14.07) Daﬀodil 181
(5.31) 17.43 (17.14) Yellow 190
m(C‚N2) (cyclic) m(NH)/(NH2) m(OH) mas(O‚S‚O)
1591 3363 3435 1410
1595 3338 3440 1388
3216
1581 3262 3328 1388
1596 3389 3486 1403
Table 3 Analytical data and some physical properties of the synthesized complexes.









(B. M.)C H N V
(1) [VO(bumphp-sdz)2(H2O)]ÆH2O
(C48H52N12O10S2V) (1070.94)
54.52 4.64 15.76 4.49 Peppermint 225 65 12.5 1.74
(54.74) (4.75) (15.96) (4.84)
(2) [VO(bumphp-sgn)2(H2O)]ÆH2O
(C42H50N12O9S2V) (980.94)
51.69 5.32 17.27 5.37 Pastel green 210 40 16.3 1.75
(51.38) (5.10) (17.13) (5.19)
(3) [VO(bumphp-snm)2(H2O)]ÆH2O
(C40H46N8O9S2V) (896.94)
53.29 5.37 12.24 5.79 Pistachio 200 50 14.2 1.78
(53.52) (5.13) (12.49 (5.68)
(4) [VO(bumphp-smr)2(H2O)]ÆH2O
(C50H54N12O9S2V) (1080.94)
55.32 5.13 15.71 4.54 Pastel green 220 50 19.2 17.6
(55.51) (5.00) (15.54) (4.71)
Table 4 Important IR spectral bands of the synthesized complexes.
S. No Complexes m(C‚N)
(azometh.)
m(C–O) (enolic) m(C‚N2) (cyclic) m(V‚O) m(V–O) m(V–N) m(OH) m(NH)/(NH2)
(1) [VO(bumphp-sdz)2(H2O)]ÆH2O 1615 1164 1591 975 639 486 3475 (br) 3348
(2) [VO(bumphp-sgn)2(H2O)]ÆH2O 1612 1150 1595 980 634 491 3470 (br) 3317
3245
(3) [VO(bumphp-snm)2(H2O)]ÆH2O 1617 1195 1585 980 634 486 3313 (br) 3230
(4) [VO(bumphp-smr)2(H2O)]ÆH2O 1607 1180 Merged with m(C‚N) 990 625 502 3450 (br) 3338
Figure 3 IR spectrum of [VO(bumphp-snm)2(H2O)]ÆH2O (3).
82 R.C. Maurya et al.The vanadium content of each of the complexes was deter-
mined as follows. One hundred milligrams of the sample of
the compound were placed in a silica crucible, decomposed
by gentle heating and then was added 1–2 mL of concentrated
HNO3, 2–3 times. An orangish mass (V2O5) was obtained after
decomposing and complete drying. It was dissolved in mini-
mum amount of dilute H2SO4, and the solution so obtainedwas diluted with distilled water to 100 mL in a measuring ﬂask.
The vanadium content of each of the complexes was deter-
mined volumetrically using decinormal KMnO4 solution as
an oxidizing agent in the presence of sulfurous acid. The
amount of vanadium in the sample solution was calculated
using the standard (Furman, 1962) relationship: 1 mL of
0.1 N KMnO4 = 5.094 mg vanadium.
Table 5 Electronic spectral data of the synthesized complexes.
S. No. Complex kmax (nm.) e (L mol
1 cm1) Peak assignment
(1) [VO(bumphp-sdz)2(H2O)]ÆH2O 320 2492 Charge transfer transition b2 ! a1
438.5 341
(2) [VO(bumphp-sgn)2(H2O)]ÆH2O 328 2894 Charge transfer transition b2 ! a1
440 270
(3) [VO(bumphp-snm)2(H2O)]ÆH2O 333 3178 Charge transfer transition b2 ! a1
433 294
(4) [VO(bumphp-smr)2(H2O)]ÆH2O 332 3238 Charge transfer transition b2 ! a1
427 267
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The following physical methods were used in the present inves-
tigation. Thermogravimety of a complex was performed on a
Perkin–Elmer Thermoanalyser at S. A. I. F., Indian Institute
of Technology, Mumbai. The solid-state infrared spectra were
obtained using KBr pellets with a Perkin–Elmer model 1620
FT-IR spectrophotometer at the Central Drug Research Insti-
tute, Lucknow. Electronic spectra were recorded on an ATI
Unicam UV-1–100 UV/vis Spectrophotometer in our labora-
tory. Conductance measurements were made in DMF solution
using a Toshniwal conductivity bridge and dip-type cell with a
smooth platinum electrode of cell constant 1.02. Magnetic
measurements were done by a vibrating sample magnetometer
at the Regional Sophisticated Instrumentation Centre, Indian
Institute of Technology, Chennai. The decomposition temper-
atures of the complexes were recorded by an electrically oper-
ated melting point apparatus (Kumar Industries, Mumbai) of
heating capacity up to 360 C. Cyclic voltammetric measure-
ments were carried out on an ECDA-001 basic electrochemis-
try system. A three-electrode system consisting of (i) a
platinum disk working electrode, (ii) a platinum wire counter
electrode and (iii) a Ag/AgCl reference electrode was used. A
10 mL glass cell with a Teﬂon cell cover holding working,
counter, and reference electrodes and deoxygenating purge
tube formed the sample cell. Prior to each run, the working
electrode was polished using polishing nylon cloth over a glass
plate. The sample solution was deoxygenated by passing puri-
ﬁed nitrogen gas through the solution. The X-Band and EPR
spectra of the complexes were measured on a Bruker ESP X-
band EPR spectrometer using powdered samples at the Regio-
nal Sophisticated Instrumentation Centre, Indian Institute of
Technology, Chennai.
2.7. 3D Molecular modeling studies
The 3D molecular modeling of one of the synthesized com-
pounds was carried out on CS Chem 3D Ultra Molecular
Modeling and Analysis Programme (www.cambridge-
soft.com). It is an interactive graphics program that allows
rapid structure building, geometry optimization, and molecu-
lar display. It has the ability to handle transition metal
compounds.
3. Results and discussion
The oxovanadium(IV) complexes were prepared according to
the following equations:VOSO4  5H2Oþ 2LH !H2O; C2H5OH
Reflux
½VOðLÞ2ðH2OÞ H2OþH2SO4
where LH= bumphp-sdzH (1), bumphp-sgnH (2), bumphp-
snmH (3), bumphp-smrH (4).
The resulting complexes are soluble in DMF and DMSO,
partially soluble in acetonitrile and insoluble in ethanol, meth-
anol, and carbon tetrachloride. They are non-hygroscopic and
colored solids. Their physical properties are given in Table 3.
3.1. Infrared spectral studies
The important spectral bands of the synthesized ligands as well
as the complexes are presented in Tables 2 and 4, respectively.
All of the Schiff base ligands in the present investigation exhi-
bit a broad band centered at 3328–3486 cm1. This suggests
the involvement of the 5-OH group in intramolecular hydro-
gen (Maurya et al., 1997) bonding with the lone pair of azome-
thine nitrogen. It also suggests that the ligands exist in enol
form in the solid state (Maurya et al., 2002a,b,c).
The Schiff base ligands used in the present investigation
contain six potential donor sites: (i) the enolic oxygen; (ii)
the cyclic nitrogen, N1; (iii) the cyclic nitrogen, N2; (iv) the azo-
methine nitrogen; (v) the sulfonamide (–SO2NH) oxygen or
nitrogen and; (vi) the ring nitrogen of sulfa drug. All the Schiff
base ligands show a sharp and strong band due to m(C‚N) of
the azomethine group at 1627–1630 cm1. The observed low-
energy shift of this band in the chelates and appearing at
1607–1617 cm1, suggests the coordination of the azomethine
nitrogen (Maurya et al., 2002a,b,c).
The m(C‚N2) (cyclic) band arising from the pyrazolone
moiety of the ligands appears at 1581–1596 cm1 and does
not show any appreciable change in its respective positions
in the complexes. This observation indicates the non-participa-
tion of the ring nitrogen N2 in coordination. The coordination
of the ring nitrogen N1 is unfavorable due to the steric demand
of the bulky phenyl ring attached to it.
The m(NH) mode of the sulfonamide group/amino group in
the uncoordinated Schiff bases remains almost unchanged in
the spectra of their complexes (see Tables 2 and 4). This sug-
gests that the sulfonamide nitrogen/amino group is not taking
part in coordination. The band appearing at 1388–1410 cm1
in the ligands is assigned to mas(O‚S‚O). This band remains
almost at the same position in the complexes and hence sug-
gests that the sulfonamide oxygen is not taking part in coordi-
nation with the metal center. The reaction of the enolic Schiff
bases with VO2+ ion with the elimination of a proton is
revealed by the presence of a new band in the complexes at
1150–1195 cm1 as compared to that of the Schiff bases at
84 R.C. Maurya et al.1138–1179 cm1 due to m(C–O) (enolic) (Maurya et al., 1996).
The appearance of a broad band centered at 3313–3475 cm1
and assignable as m(OH) suggests the presence of lattice/coor-
dinated water molecules in the complexes.
Most of the oxovanadium(IV) complexes exhibit a strong
band near 1000 cm1, which has been assigned to m(V‚O)
(Selbin, 1966). In contrast, several oxovanadium(IV) com-
plexes have been reported in which this stretching mode
appears at quite lower (Maurya et al., 2001) wave numbers,
around 900 cm1. The shift of m(V‚O) band to lower wave
numbers has been suggested due to the presence of a slight
  V‚O  V‚O   type interaction occurring between a van-
adyl oxygen of one molecule with a vanadium metal in another
molecule (Boas and Pessoa, 1987). In the present work, the
m(V‚O) mode is found at 975–990 cm1 thereby suggesting
the absence of   V‚O  V‚O   type interaction in these
complexes. The IR spectra of the Schiff base ligand
(bumphp-snmH, III) and its complex, [VO(bumphp-
snm)2(H2O)]ÆH2O (3) are given in Figs. 2 and 3, respectively.
3.2. Electronic spectral studies
The electronic spectra of these compounds were recorded in
103 M dimethylformamide solutions in the range of 280–
800 nm. The kmax of the electronic spectral peaks and the
respective molar extinction coefﬁcients along with the tentative
assignments are given in Table 5. Besides high intensity chargeFigure 4 Electronic spectrum of [VO(bumphp-sgn)2(H2O)]ÆH2O
(2).
Table 6 ESR spectral parameters of the complexes.
Compound A^ A|| Aav g^ g|| gav
[VO(bumphp-sgn)2(H2O)]ÆH2O 180 240 200 1.898 1.896 1.897
[VO(bumphp-smr)2(H2O)]ÆH2O 180 140 166.67 1.90 1.976 1.925transfer transitions, all these complexes displayed one low
intensity d–d transition which may be assigned to b2 ! 1a1
transition (Lever, 1984). The assignment of b2 ! 1a1 transition
in each case assumes idealized C2v symmetry. These spectra
are typical of oxovanadium(IV) complexes (Maurya and
Rajput, 2004; Dutta et al., 1997). The electronic spectrum of
the compound, [VO(bumphp-sgn)2(H2O)]ÆH2O (2) is shown
in Fig. 4.
3.3. ESR spectral studies
The X-band EPR spectra of compounds, (2) and (4) were
recorded using the microwave frequencies 9.09 GHz and
9.10 GHz, respectively in frozen DMF solution without DPPH
at LNT. Each spectrum shows an eight-line pattern, a charac-
teristic of an unpaired electron being coupled with a vanadium
nuclear spin (I= 7/2). This means that the unpaired electron is
in the vicinity of I= 7/2 of its own mother nucleus. Thus, the
isotropic ESR spectrum of a magnetically dilute oxovana-
dium(IV) complex gives (2 · 7/2 + 1 = 8 lines). The calcu-
lated ESR parameters from the spectra of both the
complexes are given in Table 6.
The observed gav values for both the complexes deviate
from the free ion value 2.0036, which suggest that the resulting
complexes are covalent in nature (Dutta and Syamal, 1993).
Moreover, the features of the spectra of these complexesFigure 5a ESR spectrum of [VO(bumphp-sgn)2(H2O)]ÆH2O (2).
Figure 5b ESR spectrum of [VO(bumphp-smr)2(H2O)]ÆH2O (4).
Figure 6 Thermogram of [VO(bumphp-snm)2(H2O)]ÆH2O (3).
Table 7 Some important parameters of cyclic voltammogram of the complexes.
Compd. Epc Epa Er ¼ EpcþEpa2 E(Epc  Epa) ipc ipa ipc/ipa
(1) 711.5 1115.4 913.45 403.9 155.5 133.4 1.17
(3) 615.3 961.6 788.45 346.3 160 220 0.73
Supporting electrolyte: tetrabutylammonium tetraﬂuoroborate, [CH3(CH2)3]4NBF4 (50 mmol); concentration of complexes; 1 mmol; all the
potentials are referenced to Ag/AgCl electrode; Er = 0.5(Epa + Epc), where Epa and Epc are anodic and cathodic potentials.
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(Maurya et al., 2002a,b,c). The ESR spectrum of compounds,
[VO(bumphp-sgn)2(H2O)]ÆH2O (2) and [VO(bumphp-smr)2
(H2O)]ÆH2O (4) is given in Fig. 5a and b, respectively.
3.4. Thermogravimetric studies
The thermogram of one of the representative compounds,
[VO(bumphp-snm)2(H2O)]ÆH2O (3) were recorded in the tem-
perature range from 30 to 1000 C at a heating rate of
15 C/min. This compound shows a weight loss of 4% in the
temperature range 80–140 C (calcd. wt. loss for 2 mol of
H2O, 4%). As this weight loss starts from 80 C and completes
around 140 C, this shows the presence (Maurya et al., 2003;
Zhao et al., 2008) of one lattice water and one coordinated
water molecule in the complex. After this weight loss, the com-
pound remains stable up to 300 C and thereafter, shows a
steep weight loss. The ultimate weight loss of 84% at
950 C roughly corresponds to the removal of all the ligand
moieties from the complex (calcd. wt. loss for removal of all
the ligand moieties, 92.7%). The ﬁnal residue attaining a con-
stant weight (observed, 16%) over 950 C roughly corresponds
to V2O5 (calculated, 20.27%). This weight loss data, thus,
agree well with the IR results for this complex. The thermo-
gram of compound, [VO(bumphp-snm)2(H2O)]ÆH2O (3) is
given in Fig. 6.3.5. Magnetic measurements
The magnetically dilute oxovanadium(IV) complexes usually
exhibit magnetic moments in line with spin-only value of
1.73 B.M. At room temperature, the observed value of the
magnetic moments for the present complexes, are in the range
1.74–1.76 B.M. These data suggest that the complexes under
this investigation are mononuclear (Dutta et al., 1997).
3.6. Conductance measurements
The observed molar conductances (12.5–19.7 ohm1 cm2 mol1)
in 103 M DMF solutions of these Schiff base complexes are
given in Table 3, and are consistent with the non-electrolytic
nature of the complexes. Such a non-zero molar conductance
value for each of the complexes in the present study is most
probably due to the strong donor capacity of DMF, which
may lead to the displacement of anionic ligand and change
of electrolyte (Geary, 1971) type.
3.7. Cyclic voltammetric studies
Cyclic voltammetric measurements of two representative com-
plexes, [VO(bumphp-sdz)2(H2O)]ÆH2O (1) and [VO(bumphp-
snm)2(H2O)]ÆH2O (3), were carried out on an ECDA-001 basic
electrochemistry system in order to assess the suitability of
Table 8 Various bond lengths of compound [VO(bumphp-sdz)2(H2O)]ÆH2O (1).
S. No. Atoms Actual bond length Optimal bond length S. No. Atoms Actual bond length Optimal bond length
1 C(76)–H(134) 1.113 1.113 71 C(36)–C(37) 1.337 1.42
2 C(76)–H(133) 1.113 1.113 72 C(35)–H(109) 1.1 1.1
3 C(76)–H(132) 1.113 1.113 73 C(35)–C(36) 1.337 1.42
4 C(76)–H(131) 1.113 1.113 74 C(34)–H(108) 1.1 1.1
5 C(2)–H(84) 1.113 1.113 75 C(34)–C(35) 1.337 1.42
6 C(2)–H(83) 1.113 1.113 76 C(33)–H(107) 1.1 1.1
7 C(2)–H(82) 1.113 1.113 77 C(33)–C(34) 1.337 1.42
8 C(2)–H(81) 1.113 1.113 78 C(32)–C(37) 1.337 1.42
9 C(1)–H(80) 1.113 1.113 79 C(32)–C(33) 1.337 1.42
10 C(1)–H(79) 1.113 1.113 80 C(31)–H(106) 1.113 1.113
11 C(1)–H(78) 1.113 1.113 81 C(31)–H(105) 1.113 1.113
12 C(1)–H(77) 1.113 1.113 82 C(30)–H(104) 1.113 1.113
13 N(75)–H(130) 1.05 1.05 83 C(30)–H(103) 1.113 1.113
14 C(74)–H(129) 1.1 1.1 84 C(30)–C(31) 1.523 1.523
15 C(73)–H(128) 1.1 1.1 85 C(29)–H(102) 1.113 1.113
16 C(73)–C(74) 0.9398 1.42 86 C(29)–H(101) 1.113 1.113
17 C(72)–H(127) 1.1 1.1 87 C(29)–H(100) 1.113 1.113
18 C(72)–C(73) 1.337 1.42 88 C(29)–C(30) 1.523 1.523
19 N(71)–C(72) 1.26 1.358 89 N(39)–C(28) 1.266 1.266
20 C(70)–N(75) 1.266 1.462 90 C(28)–C(31) 1.497 1.497
21 C(70)–N(71) 1.26 1.358 91 C(26)–O(27) 1.355 1.355
22 C(74)–N(69) 1.26 1.358 92 C(25)–C(28) 1.337 1.503
23 N(69)–C(70) 1.26 1.358 93 C(25)–C(26) 1.337 1.337
24 N(75)–S(66) 1.696 – 94 C(24)–C(38) 1.497 1.497
25 S(66)–O(68) 1.45 1.45 95 C(24)–C(25) 1.337 1.503
26 S(66)–O(67) 1.45 1.45 96 N(23)–C(24) 1.5526 1.26
27 C(65)–H(126) 1.1 1.1 97 N(22)–C(32) 1.266 1.462
28 C(64)–S(66) 1.79 – 98 N(22)–C(26) 1.266 1.462
29 C(64)–C(65) 1.337 1.42 99 N(22)–N(23) 1.23 1.426
30 C(63)–H(125) 1.1 1.1 100 N(39)–V(21) 2.075 –
31 C(63)–C(64) 1.337 1.42 101 V(21)–O(50) 1.86 –
32 C(62)–H(124) 1.1 1.1 102 V(21)–O(49) 1.5996 –
33 C(62)–C(63) 1.337 1.42 103 O(27)–V(21) 1.86 –
34 C(61)–C(62) 1.337 1.42 104 C(20)–H(99) 1.113 1.113
35 C(60)–H(123) 1.1 1.1 105 C(20)–H(98) 1.113 1.113
36 C(65)–C(60) 1.337 1.42 106 C(20)–H(97) 1.113 1.113
37 C(60)–C(61) 1.337 1.42 107 C(19)–H(96) 1.1 1.1
38 N(59)–H(122) 1.05 1.05 108 C(18)–H(95) 1.1 1.1
39 C(58)–H(121) 1.1 1.1 109 C(18)–C(19) 1.337 1.42
40 C(57)–H(120) 1.1 1.1 110 C(17)–H(94) 1.1 1.1
41 C(57)–C(58) 0.9398 1.42 111 C(17)–C(18) 1.337 1.42
42 C(56)–H(119) 1.1 1.1 112 C(16)–H(93) 1.1 1.1
43 C(56)–C(57) 1.337 1.42 113 C(16)–C(17) 1.337 1.42
44 N(55)–C(56) 1.26 1.358 114 C(15)–H(92) 1.1 1.1
45 C(54)–N(59) 1.266 1.462 115 C(15)–C(16) 1.337 1.42
46 C(54)–N(55) 1.26 1.358 116 C(14)–C(19) 1.337 1.42
47 C(58)–N(53) 1.26 1.358 117 C(14)–C(15) 1.337 1.42
48 N(53)–C(54) 1.26 1.358 118 C(13)–H(91) 1.113 1.113
49 O(50)–H(52) 0.986 – 119 C(13)–H(90) 1.113 1.113
50 O(50)–H(51) 0.986 – 120 C(12)–H(89) 1.113 1.113
51 N(59)–S(46) 1.696 – 121 C(12)–H(88) 1.113 1.113
52 S(46)–O(48) 1.45 1.45 122 C(12)–C(13) 1.523 1.523
53 S(46)–O(47) 1.45 1.45 123 C(11)–H(87) 1.113 1.113
54 C(45)–H(118) 1.1 1.1 124 C(11)–H(86) 1.113 1.113
55 C(44)–S(46) 1.79 – 125 C(11)–H(85) 1.113 1.113
56 C(44)–C(45) 1.337 1.42 126 C(11)–C(12) 1.523 1.523
57 C(43)–H(117) 1.1 1.1 127 V(21)–N(10) 1.8628 –
58 C(43)–C(44) 1.337 1.42 128 C(41)–N(10) 1.266 1.462
59 C(42)–H(116) 1.1 1.1 129 C(9)–C(13) 1.497 1.497
60 C(42)–C(43) 1.337 1.42 130 C(9)–N(10) 1.266 1.266
61 C(41)–C(42) 1.337 1.42 131 O(8)–V(21) 1.86 –
62 C(40)–H(115) 1.1 1.1 132 C(7)–O(8) 1.355 1.355
63 C(45)–C(40) 1.337 1.42 133 C(6)–C(9) 1.337 1.503
64 C(40)–C(41) 1.337 1.42 134 C(6)–C(7) 1.337 1.337
65 C(61)–N(39) 1.266 1.462 135 C(5)–C(20) 1.497 1.497
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Table 8 (continued)
S. No. Atoms Actual bond length Optimal bond length S. No. Atoms Actual bond length Optimal bond length
66 C(38)–H(114) 1.113 1.113 136 C(5)–C(6) 1.337 1.503
67 C(38)–H(113) 1.113 1.113 137 N(4)–C(5) 1.26 1.26
68 C(38)–H(112) 1.113 1.113 138 N(3)–C(14) 1.266 1.462
69 C(37)–H(111) 1.1 1.1 139 N(3)–C(7) 1.266 1.462
70 C(36)–H(110) 1.1 1.1 140 N(3)–N(4) 1.614 1.426
Table 9 Various bond angles of compound [VO(bumphp-sdz)2(H2O)]ÆH2O (1).








1 H(134)–C(76)–H(133) 109.52 109.47 122 H(109)–C(35)–C(36) 119.9999 120
2 H(134)–C(76)–H(132) 109.4621 109.47 123 H(109)–C(35)–C(34) 120 120
3 H(134)–C(76)–H(131) 109.4618 109.47 124 C(36)–C(35)–C(34) 120.0001 –
4 H(133)–C(76)–H(132) 109.4417 109.47 125 H(108)–C(34)–C(35) 120.0004 120
5 H(133)–C(76)–H(131) 109.4417 109.47 126 H(108)–C(34)–C(33) 119.9996 120
6 H(132)–C(76)–H(131) 109.4999 109.47 127 C(35)–C(34)–C(33) 120 –
7 H(84)–C(2)–H(83) 109.52 109.47 128 H(111)–C(37)–C(36) 119.9993 120
8 H(84)–C(2)–H(82) 109.4619 109.47 129 H(111)–C(37)–C(32) 120.0003 120
9 H(84)–C(2)–H(81) 109.462 109.47 130 C(36)–C(37)–C(32) 120.0004 –
10 H(83)–C(2)–H(82) 109.4417 109.47 131 H(107)–C(33)–C(34) 119.9998 120
11 H(83)–C(2)–H(81) 109.4419 109.47 132 H(107)–C(33)–C(32) 120.0003 120
12 H(82)–C(2)–H(81) 109.4999 109.47 133 C(34)–C(33)–C(32) 119.9999 –
13 H(80)–C(1)–H(79) 109.5197 109.47 134 C(37)–C(32)–C(33) 119.9999 120
14 H(80)–C(1)–H(78) 109.4619 109.47 135 C(37)–C(32)–N(22) 120.0003 120
15 H(80)–C(1)–H(77) 109.4618 109.47 136 C(33)–C(32)–N(22) 119.9998 120
16 H(79)–C(1)–H(78) 109.4421 109.47 137 H(114)–C(38)–H(113) 109.5199 109
17 H(79)–C(1)–H(77) 109.4416 109.47 137 H(114)–C(38)–H(112) 109.462 109
18 H(78)–C(1)–H(77) 109.5001 109.47 139 H(114)–C(38)–C(24) 109.4619 110
19 H(129)–C(74)–C(73) 114.0213 120 140 H(113)–C(38)–H(112) 109.4419 109
20 H(129)–C(74)–N(69) 114.0215 116.5 141 H(113)–C(38)–C(24) 109.4419 110
21 C(73)–C(74)–N(69) 131.9572 123.5 142 H(112)–C(38)–C(24) 109.4998 110
22 H(128)–C(73)–C(74) 120.979 120 143 C(24)–N(23)–N(22) 108.8313 115
23 H(128)–C(73)–C(72) 120.978 120 144 C(62)–C(61)–C(60) 120.0004 120
24 C(74)–C(73)–C(72) 118.043 – 145 C(62)–C(61)–N(39) 120.0001 120
25 H(127)–C(72)–C(73) 120 120 146 C(60)–C(61)–N(39) 119.9995 120
26 H(127)–C(72)–N(71) 119.9999 116.5 147 H(106)–C(31)–H(105) 109.5206 109.4
27 C(73)–C(72)–N(71) 120.0001 123.5 148 H(106)–C(31)–C(30) 109.462 109.41
28 C(72)–N(71)–C(70) 115.0002 115 149 H(106)–C(31)–C(28) 109.4618 109.41
29 C(74)–N(69)–C(70) 114.9998 115 150 H(105)–C(31)–C(30) 109.4417 109.41
30 N(75)–C(70)–N(71) 120.0004 126 151 H(105)–C(31)–C(28) 109.4415 109.41
31 N(75)–C(70)–N(69) 119.9998 126 152 C(30)–C(31)–C(28) 109.4997 109.5
32 N(71)–C(70)–N(69) 119.9998 120 153 N(39)–C(28)–C(31) 120 125.3
33 H(130)–N(75)–C(70) 120.0004 118 154 N(39)–C(28)–C(25) 120.0001 120
34 H(130)–N(75)–S(66) 119.9996 – 155 C(31)–C(28)–C(25) 119.9999 121.4
35 C(70)–N(75)–S(66) 120 – 156 C(38)–C(24)–C(25) 130.9156 121.4
36 H(121)–C(58)–C(57) 114.0221 120 157 C(38)–C(24)–N(23) 130.9152 115.1
37 H(121)–C(58)–N(53) 114.0215 116.5 158 C(25)–C(24)–N(23) 98.1693 120
38 C(57)–C(58)–N(53) 131.9564 123.5 159 C(32)–N(22)–C(26) 124.5002 124
39 H(120)–C(57)–C(58) 120.9782 120 160 C(32)–N(22)–N(23) 124.4997 124
40 H(120)–C(57)–C(56) 120.9783 120 161 C(26)–N(22)–N(23) 111.0001 124
41 C(58)–C(57)–C(56) 118.0436 – 162 C(28)–C(25)–C(26) 119.9983 120
42 H(119)–C(56)–C(57) 119.9999 120 163 C(28)–C(25)–C(24) 128.9979 120
43 H(119)–C(56)–N(55) 120 116.5 164 C(26)–C(25)–C(24) 111.0003 120
44 C(57)–C(56)–N(55) 120.0001 123.5 165 O(27)–C(26)–C(25) 124.3002 124.3
45 C(56)–N(55)–C(54) 114.9999 115 166 O(27)–C(26)–N(22) 124.6986 –
46 C(58)–N(53)–C(54) 115.0001 115 167 C(25)–C(26)–N(22) 110.9991 120
47 N(59)–C(54)–N(55) 119.9999 126 168 H(95)–C(18)–C(19) 119.9998 120
48 N(59)–C(54)–N(53) 120.0001 126 169 H(95)–C(18)–C(17) 119.9999 120
49 N(55)–C(54)–N(53) 120 120 170 C(19)–C(18)–C(17) 120.0003 –
50 H(122)–N(59)–C(54) 119.9998 118 171 H(94)–C(17)–C(18) 120.0005 120
51 H(122)–N(59)–S(46) 120.0003 – 172 H(94)–C(17)–C(16) 120 120
(continued on next page)
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52 C(54)–N(59)–S(46) 119.9999 – 173 C(18)–C(17)–C(16) 119.9995 –
53 H(102)–C(29)–H(101) 109.5203 109 174 H(93)–C(16)–C(17) 119.9998 120
54 H(102)–C(29)–H(100) 109.461 109 175 H(93)–C(16)–C(15) 119.9998 120
55 H(102)–C(29)–C(30) 109.462 110 176 C(17)–C(16)–C(15) 120.0004 –
56 H(101)–C(29)–H(100) 109.4418 109 177 H(96)–C(19)–C(18) 120.0001 120
57 H(101)–C(29)–C(30) 109.4421 110 178 H(96)–C(19)–C(14) 119.9999 120
58 H(100)–C(29)–C(30) 109.5 110 179 C(18)–C(19)–C(14) 120.0001 –
59 H(104)–C(30)–H(103) 109.52 109.4 180 H(92)–C(15)–C(16) 120.0007 120
60 H(104)–C(30)–C(31) 109.462 109.41 181 H(92)–C(15)–C(14) 119.9993 120
61 H(104)–C(30)–C(29) 109.462 109.41 182 C(16)–C(15)–C(14) 120 –
62 H(103)–C(30)–C(31) 109.4419 109.41 183 H(52)–O(50)–H(51) 119.9998 –
63 H(103)–C(30)–C(29) 109.4418 109.41 184 H(52)–O(50)–V(21) 120 –
64 C(31)–C(30)–C(29) 109.4996 109.5 185 H(51)–O(50)–V(21) 120.0003 –
65 H(87)–C(11)–H(86) 109.52 109 186 C(61)–N(39)–C(28) 121.5436 124
66 H(87)–C(11)–H(85) 109.4613 109 187 C(61)–N(39)–V(21) 121.544 –
67 H(87)–C(11)–C(12) 109.4615 110 188 C(28)–N(39)–V(21) 116.9124 –
68 H(86)–C(11)–H(85) 109.442 109 189 C(26)–O(27)–V(21) 109.4998 –
69 H(86)–C(11)–C(12) 109.4424 110 190 C(42)–C(41)–C(40) 119.9999 120
70 H(85)–C(11)–C(12) 109.5 110 191 C(42)–C(41)–N(10) 120 120
71 H(89)–C(12)–H(88) 109.5197 109.4 192 C(40)–C(41)–N(10) 120.0001 120
72 H(89)–C(12)–C(13) 109.4615 109.41 193 O(50)–V(21)–O(49) 128.1267 –
73 H(89)–C(12)–C(11) 109.4619 109.41 194 O(50)–V(21)–N(39) 134.7233 –
74 H(88)–C(12)–C(13) 109.4416 109.41 195 O(50)–V(21)–O(27) 102.8229 –
75 H(88)–C(12)–C(11) 109.4424 109.41 196 O(50)–V(21)–N(10) 121.5001 –
76 C(13)–C(12)–C(11) 109.5003 109.5 197 O(50)–V(21)–O(8) 129.5918 –
77 N(75)–S(66)–O(68) 109.4417 – 198 O(49)–V(21)–N(39) 97.0934 –
78 N(75)–S(66)–O(67) 109.4419 – 199 O(49)–V(21)–O(27) 90.0001 –
79 N(75)–S(66)–C(64) 109.52 – 200 O(49)–V(21)–N(10) 19.5346 –
80 O(68)–S(66)–O(67) 109.4999 116.6 201 O(49)–V(21)–O(8) 90.0001 –
81 O(68)–S(66)–C(64) 109.4619 – 202 N(39)–V(21)–O(27) 76.1516 –
82 O(67)–S(66)–C(64) 109.4619 – 203 N(39)–V(21)–N(10) 100.2237 –
83 H(126)–C(65)–C(64) 120.0002 120 204 N(39)–V(21)–O(8) 34.1154 –
84 H(126)–C(65)–C(60) 119.9995 120 205 O(27)–V(21)–N(10) 109.5001 –
85 C(64)–C(65)–C(60) 120.0003 – 206 O(27)–V(21)–O(8) 109.5002 –
86 S(66)–C(64)–C(65) 120.0001 – 207 N(10)–V(21)–O(8) 82.5412 –
87 S(66)–C(64)–C(63) 120.0002 – 208 H(91)–C(13)–H(90) 109.52 109.4
88 C(65)–C(64)–C(63) 119.9997 120 209 H(91)–C(13)–C(12) 109.4615 109.41
89 H(125)–C(63)–C(64) 119.9998 120 210 H(91)–C(13)–C(9) 109.4618 109.41
90 H(125)–C(63)–C(62) 120.0002 120 211 H(90)–C(13)–C(12) 109.4417 109.41
91 C(64)–C(63)–C(62) 119.9999 – 212 H(90)–C(13)–C(9) 109.4421 109.41
92 H(124)–C(62)–C(63) 119.9995 120 213 C(12)–C(13)–C(9) 109.5002 109.5
93 H(124)–C(62)–C(61) 120.0004 120 214 C(41)–N(10)–V(21) 118.6942 –
94 C(63)–C(62)–C(61) 120.0001 – 215 C(41)–N(10)–C(9) 118.6943 124
95 H(123)–C(60)–C(65) 120.0003 120 216 V(21)–N(10)–C(9) 122.6116 –
96 H(123)–C(60)–C(61) 120.0002 120 217 C(19)–C(14)–C(15) 119.9997 120
97 C(65)–C(60)–C(61) 119.9995 – 218 C(19)–C(14)–N(3) 120 120
98 N(59)–S(46)–O(48) 109.4422 – 219 C(15)–C(14)–N(3) 120.0003 120
99 N(59)–S(46)–O(47) 109.4417 – 220 C(13)–C(9)–N(10) 119.9999 125.3
100 N(59)–S(46)–C(44) 109.5202 – 221 C(13)–C(9)–C(6) 120 121.4
101 O(48)–S(46)–O(47) 109.4998 116.6 222 N(10)–C(9)–C(6) 120.0001 120
102 O(48)–S(46)–C(44) 109.4617 – 223 V(21)–O(8)–C(7) 109.4998 –
103 O(47)–S(46)–C(44) 109.4617 – 224 O(8)–C(7)–C(6) 124.2983 124.3
104 H(118)–C(45)–C(44) 120.0003 120 225 O(8)–C(7)–N(3) 124.6983 –
105 H(118)–C(45)–C(40) 120 120 226 C(6)–C(7)–N(3) 111 120
106 C(44)–C(45)–C(40) 119.9998 – 227 H(99)–C(20)–H(98) 109.5198 109
107 S(46)–C(44)–C(45) 119.9998 – 228 H(99)–C(20)–H(97) 109.4618 109
108 S(46)–C(44)–C(43) 119.9995 – 229 H(99)–C(20)–C(5) 109.4619 110
109 C(45)–C(44)–C(43) 120.0007 120 230 H(98)–C(20)–H(97) 109.4418 109
110 H(117)–C(43)–C(44) 120.0005 120 231 H(98)–C(20)–C(5) 109.4419 110
111 H(117)–C(43)–C(42) 120.0002 120 232 H(97)–C(20)–C(5) 109.5001 110
112 C(44)–C(43)–C(42) 119.9993 – 233 C(9)–C(6)–C(7) 119.9986 120
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113 H(116)–C(42)–C(43) 119.9997 120 234 C(9)–C(6)–C(5) 128.998 120
114 H(116)–C(42)–C(41) 120 120 235 C(7)–C(6)–C(5) 111 120
115 C(43)–C(42)–C(41) 120.0003 236 C(14)–N(3)–C(7) 128.3535 124
116 H(115)–C(40)–C(45) 120.0002 120 237 C(14)–N(3)–N(4) 128.3536 124
117 H(115)–C(40)–C(41) 119.9998 120 237 C(7)–N(3)–N(4) 103.2929 124
118 C(45)–C(40)–C(41) 120 239 C(20)–C(5)–C(6) 124.5 121.4
119 H(110)–C(36)–C(37) 120.0002 120 240 C(20)–C(5)–N(4) 124.5001 115.1
120 H(110)–C(36)–C(35) 120.0001 120 241 C(6)–C(5)–N(4) 110.9999 120
121 C(37)–C(36)–C(35) 119.9997 242 C(5)–N(4)–N(3) 103.7073 115
Figure 7 Cyclic voltammogram of [VO(bumphp-snm)2(H2O)]Æ
H2O (3).
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tron transfer reactions. The complexes were dissolved in dim-
thyformamide and the cyclic voltammograms were recorded
in the scan range of 2000 to 2000 mV. The reduction of theseFigure 8 3D structure of [VO(bcomplexes to +III oxidation state (usually expected in such
complexes) were achieved by waves with Er values (Maurya
and Rajput, 2004; Dai et al., 1996) in the range from
788.45 to 913.45 mV against the saturated Ag/AgCl elec-
trode (Table 7). Other important parameters are also included
in this table. The deviations of ipc/ipa from 1 in the present
cases suggest that the redox couple is not reversible. This
may be due to a slow electron transfer reaction. This is again
reﬂected by the unusually high values of DE in the range of
346.3–403.9 mV, not following the reversibility criterion
(Kissinger and Heineman, 1984),
DEp ¼ Epa  Epc ¼ 0:059
n
The cyclic voltammogram of compound (3) is shown in Fig. 7.
3.8. 3D-Molecular modeling and analysis
In view of the hexa-coordination of all the complexes (vide
infra), and also taking into account the well established square
pyramidal structure (Sakurai et al., 1995) of bis(picolina-
to)oxovanadium(IV) [having two monoprotic bidentate





































Figure 9 Proposed octahedral structure of oxovanadium(IV) complexes.
90 R.C. Maurya et al.O,N-donor sulfa drug based Schiff base ligands (LH) used in
the present investigation, and occupying equatorial positions
cis to each other, and oxo group at one of the axial positions],
the molecular modeling of a representative compound, [VO
(bumphp-sdz)2(H2O)]ÆH2O (1) is based on its octahedral struc-
ture with an axial oxo group and water molecule trans to O
(oxo) and two O,N-donor LH ligands at the equatorial posi-
tions cis to each other. The details of bond lengths and bond
angles as per the 3D structure (Fig. 8) are given in Tables 8
and 9, respectively. For convenience of looking over the differ-
ent bond lengths and bond angles, the various atoms in the
compound in question are numbered in Arabic numerals. In
all, 382 measurements of the bond lengths (140 in number),
plus the bond angles (242 in number) are listed in the Tables
8 and 9. Except few cases, optimal values of both the bond
lengths and the bond angles are given in the Tables along with
the calculated ones. The actual (calculated) bond lengths/bond
angles given in Tables are obtained as a result of energy opti-
mization in CHEM 3D Ultra, while the optimal bond length/
optimal bond angle values are the most desirable/favorable
(standard) bond lengths/bond angles established by the builder
unit of the CHEM 3D. The missing of some values of standard
bond lengths/bond angles may be due to the limitations of the
software, which we had already noticed in modeling of other
systems (Maurya et al., 2007, 2008, in press). In most of the
cases, the actual bond lengths and bond angles are close to
the optimal values, and thus the proposed structure of the
compound (1) as well as of the others are acceptable (Maurya
and Rajput, 2007; Maurya et al., 2007, 2008, in press).4. Conclusions
The satisfactory analytical data coupled with the studies pre-
sented above suggest that the complexes prepared in this inves-
tigation are of the general composition [VO(L)2(H2O)]ÆH2O,
where LH= bumphp-sdzH (1), bumphp-sgnH (2), bumphp-
snmH (3) or bumphp-smrH (4). Keeping view of the mono-meric hexacoordination of all the complexes, and the well
established square pyramidal structure (Sakurai et al., 1995)
of bis(picolinato)oxovanadium(IV) [involving a monobasic
bidentate (O,N)-donor picolinate ligand similar to monobasic
(O,N)-donor sulfa drug Schiff base ligands LH in the present
investigation, and occupying equatorial positions cis to each
other, and oxo group at one of the axial positions], octahedral
structures (Fig. 9) with an axial oxo group and a water mole-
cule trans to O (oxo), and two O,N-donor LH ligands at the
equatorial positions cis to each other, have been proposed
for these complexes. We have already proposed a similar octa-
hedral structure (Maurya et al., 2002a,b,c) for hexa-coordinated
oxovanadium(IV) complexes of the compositions, [VO(L1)2-
(H2O)] where, L
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